Comparison 26. Topical retinoids: bexarotene 1% gel versus bexarotene with corticosteroids.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Primary: investigator‐rated good/excellent control of symptoms (> 90% clearance)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 Bexarotene only (A) vs bexarotene + mometasone (B)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Bexarotene only (A) vs bexarotene + hydrocortisone (B)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 Bexarotene + mometasone (A) vs bexarotene + hydrocortisone (B)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Primary: adverse events bexarotene vs bexarotene + mometasone	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.1 Irritation/rash	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Stinging/burning	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 Exacerbation of dermatitis	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Primary: adverse events bexarotene vs bexarotene + hydrocortisone	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.1 Irritation/rash	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 Stinging/burning	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.3 Exacerbation of dermatitis	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Secondary: investigator‐rated reduction in severity (> 50% reduction in hand eczema area and severity index (HEASI))	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4.1 Bexarotene (A) only vs bexarotene + mometasone (B)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 Bexarotene (A) only vs bexarotene + hydrocortisone (B)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 Bexarotene + mometasone (A) vs bexarotene + hydrocortisone (B)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]